Metadon Ep (Methadone Hydrochloride)

• Methadone is used within the opioid pathway to manage dependence and pain.
• Opioid dependence: reduces cravings and alleviates withdrawal symptoms in patients undergoing maintenance therapy.
• Chronic pain: offers long‑acting analgesia for persistent pain conditions when other treatments are insufficient.
• Opioid detoxification: facilitates a controlled transition from illicit opioid use to abstinence under medical supervision.

• Methadone acts as a full agonist at the mu‑opioid receptors in the central nervous system, producing analgesic effects and diminishing the physiological response to opioid withdrawal. By occupying these receptors, it prevents the euphoric effects of other opioids while providing a stable level of opioid activity, thereby reducing cravings and stabilizing patients during maintenance therapy.

Methadone may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects

• Nausea: mild to moderate stomach upset.
• Constipation: reduced bowel motility.
• Drowsiness: increased sleepiness or fatigue.
• Dry mouth: reduced salivation.

Serious or Rare Side Effects

• Respiratory depression: slowed breathing, potentially life‑threatening.
• QT interval prolongation: risk of cardiac arrhythmias.
• Severe hypotension: marked drop in blood pressure.
• Allergic reactions: rash, itching, or anaphylaxis.

Methadone requires careful clinical oversight due to its pharmacologic profile.

• Assess cardiac risk: monitor QT interval and correct electrolyte imbalances.
• Avoid abrupt discontinuation: taper dose under medical supervision to prevent withdrawal.
• Use caution in hepatic impairment: adjust dosing as liver function declines.
• Monitor for respiratory depression: especially in opioid‑naïve or high‑risk patients.
• Store at ambient temperature: keep in the original container, protect from moisture and light.

Methadone interacts with several drug classes that may alter its safety or efficacy.

Major Interactions (Avoid)

• Concomitant CNS depressants (e.g., benzodiazepines, barbiturates): risk of profound respiratory depression.
• QT‑prolonging agents (e.g., certain antiarrhythmics, macrolide antibiotics): increased risk of cardiac arrhythmia.

Moderate Interactions (Monitor Closely)

• CYP3A4 inhibitors (e.g., erythromycin, ketoconazole): may raise methadone plasma levels.
• CYP3A4 inducers (e.g., rifampin, carbamazepine): may lower methadone concentrations.
• Selective serotonin reuptake inhibitors: potential for serotonin syndrome.
• Alcohol: additive central nervous system depression.